For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose:
The purpose of this trial is to evaluate the safety, tolerability, and efficacy of pembrolizumab (MK-3475, KEYTRUDA®) in hematologic malignancies. The primary study hypotheses are that treatment with pembrolizumab will result in a clinically meaningful improvement in Objective Response Rate (ORR) or Complete Remission Rate (CRR)
Status:
Recruiting
Study Date:
Fri, 11/01/2013 to Sun, 01/01/2017
Bone Marrow Disease(s):
myelodysplastic syndromes (MDS)
Associated Drug(s):
Intervention:
Biological: Pembrolizumab
IV infusion
Other Names:
MK-3475
KEYTRUDA®
Drug: Lenalidomide
oral capsules
Other Name: REVLIMID®